CA2341522A1 - Nouvelle forme saline pharmaceutique - Google Patents

Nouvelle forme saline pharmaceutique Download PDF

Info

Publication number
CA2341522A1
CA2341522A1 CA002341522A CA2341522A CA2341522A1 CA 2341522 A1 CA2341522 A1 CA 2341522A1 CA 002341522 A CA002341522 A CA 002341522A CA 2341522 A CA2341522 A CA 2341522A CA 2341522 A1 CA2341522 A1 CA 2341522A1
Authority
CA
Canada
Prior art keywords
salt
agent
base
useful
saccharinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341522A
Other languages
English (en)
Inventor
James W. Rayburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341522A1 publication Critical patent/CA2341522A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un sel de saccharinate de bases organiques médicinales qui ne sont pas des alcaloïdes, et constituant une nouvelle forme saline présentant des propriétés organoleptiques améliorées et une solubilité réduite.
CA002341522A 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique Abandoned CA2341522A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9815498P 1998-08-27 1998-08-27
US60/098,154 1998-08-27
PCT/US1999/019575 WO2000012067A1 (fr) 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique

Publications (1)

Publication Number Publication Date
CA2341522A1 true CA2341522A1 (fr) 2000-03-09

Family

ID=22267557

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341522A Abandoned CA2341522A1 (fr) 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique

Country Status (6)

Country Link
EP (1) EP1107738A4 (fr)
JP (1) JP2003525855A (fr)
CN (1) CN1348363A (fr)
AU (1) AU6021199A (fr)
CA (1) CA2341522A1 (fr)
WO (1) WO2000012067A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177294A1 (fr) 2022-03-18 2023-09-21 Plethora Therapeutics B.V. Administration transmucosale de composés psychoactifs

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
DE10013712A1 (de) * 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10130504B4 (de) 2001-06-25 2005-02-03 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Xanthin- und Phenazon-Acesulfam-H-Komplexe mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009074351A2 (fr) * 2007-12-12 2009-06-18 Ultimorphix Technologies B.V. Formes solides de ténofovir disoproxil
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
DE202010001237U1 (de) 2010-01-21 2010-04-01 Grünenthal GmbH Kombination aus Tramadol und Acetaminophen als Brausetablette
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
TW201517906A (zh) * 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN107868117B (zh) * 2016-09-28 2021-04-23 中国科学院苏州纳米技术与纳米仿生研究所 司坦唑醇糖精盐及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1288002A (fr) * 1954-06-14 1962-03-24 Pfizer & Co C Perfectionnements apportés aux procédés de fabrication de composés d'imidazoline
ES271829A1 (es) * 1960-12-19 1962-03-01 Tanabe Seiyaku Co Un procedimiento para preparar una sal comestible de acido benzofenoma-2-carboxilico y 1-metil-3-(di-2-tienilmetilen) piperidina
US4711784A (en) * 1986-01-07 1987-12-08 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177294A1 (fr) 2022-03-18 2023-09-21 Plethora Therapeutics B.V. Administration transmucosale de composés psychoactifs
NL2031332B1 (en) * 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds

Also Published As

Publication number Publication date
CN1348363A (zh) 2002-05-08
JP2003525855A (ja) 2003-09-02
AU6021199A (en) 2000-03-21
WO2000012067A1 (fr) 2000-03-09
EP1107738A1 (fr) 2001-06-20
EP1107738A4 (fr) 2003-01-22

Similar Documents

Publication Publication Date Title
CA2341522A1 (fr) Nouvelle forme saline pharmaceutique
US5811436A (en) Oral liquid compositions containing paroxetine resinate
US6306904B1 (en) Antihistaminic/antitussive compositions
US20030083354A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
EP1082109B1 (fr) Composition orale comprenant un biguanide et un acide organique
US6037358A (en) Decongestant/antihistaminic compositions
EP1778183B1 (fr) Compositions liquides de paroxetine
HU204994B (en) Process for producint new ranitidine derivatives and pharmaceutical compositions comprising same
US3976787A (en) Pharmaceutical guanidine preparations and methods of using same
JP3465820B2 (ja) トロバフロキサシン経口懸濁剤
US6462094B1 (en) Decongestant/expectorant compositions
EP1747781B1 (fr) Preparation pharmaceutique orale de fosfomycine stable et destinee a des diabetiques
EP0194336A2 (fr) Formulation orale de mobenzoxamine
SK15472001A3 (sk) Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu liečiva použiteľného na liečenie alebo prevenciu porúch nálady, porúch adaptácie alebo stavov úzkosti a depresie
CA2008183C (fr) Composition pharmaceutique liquide pour derives du piperidinealcanol
EP1452169A1 (fr) Compositions pharmaceutiques liquides de base aqueuse en forme de suspension destinnees a l'administration par voie orale d'ibuprofene
MXPA01000867A (en) Novel pharmaceutical salt form
HU187626B (en) Process for preparing vincamine saccharinate
US20040132827A1 (en) Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US6586469B2 (en) Antihistaminic/antitussive compositions
WO2003086356A1 (fr) Compositions de formes dosifiees solides de tannate de diphenhydramine et procedes d'utilisation associes
US6566396B2 (en) Antitussive/antihistaminic compositions
JPS6350355B2 (fr)
US20030044461A1 (en) Antitussive/expectorant compositions
CA1117528A (fr) Phosphate de glaucine

Legal Events

Date Code Title Description
FZDE Dead